The successful application of cancer gene therapy has been hampered by the low efficiency of in vivo gene delivery by currently used replication-defective vectors. Accordingly, considerable efforts are now being directed toward development and use of vectors capable of replicating in cancer cells. However, for replicating retroviruses, insertion of additional reading frames into the viral genome often resulted in the generation of unstable viruses. Here, we report a novel concept for the generation of replicationcompetent murine leukemia virus (MLV) vectors capable of mediating the secretion of soluble therapeutic proteins from infected cells. As a proof of principle, we inserted transgene regions encoding either a single-chain variable region fragment (scFv), here, the laminin-specific L36-scFv, or the T-cell-specific 7A5-scFv, or the cytokine GM-CSF into the MLV envelope (env) gene after þ 1 codon of the envelope (Env) protein, followed by a sequence specifying a furin protease cleavage site. The resulting viruses, termed L36-furin-A, 7A5-furin-A and GMCSF-furin-Mo, respectively, infected a variety of human cell lines, including HMEC-1 (endothelial), A301 (lymphoid), MDA-MB231 and MDA-MB468 (breast cancer) and HT1080 (fibrosarcoma) cells. Western blot analysis of conditioned culture medium from HT1080 cells infected by replicating L36-furin A, as an example, revealed that more than 90% of the Env fusion protein molecules were indeed intracellularly cleaved. After 5 days of infection, up to 3-4 mg/ml of soluble L36-scFv accumulated in the supernatant of HT1080 cells. The eukaryotically produced L36-scFv and 7A5-scFv were able to recognize their native antigens with high avidity, as assessed by ELISA and flow cytometry. Furthermore, the replicating viruses were genetically stable for more than 12 cell passages. In conclusion, a new generation of replication-competent retroviral vectors capable of mediating long-term and efficient secretion of therapeutic proteins suitable for cancer therapy was generated.
G ene-based therapies for cancer as a novel treatment modality have been intensively exploited over the last decade, in general, however, with less than satisfactory results.
1,2 A major obstacle is the inadequate transgene expression and poor distribution of replicationincompetent viral vectors within solid tumors. For instance, even after direct in vivo (intratumoral) administration, nonreplicating retroviral and adenoviral vectors -the two most widely used gene delivery systems to date, mediated transgene expression in only a small proportion (o10%) of a tumor. 1, 3, 4 Therefore, additional strategies must be developed before cancer gene therapy will become a considerable therapeutic option.
One appealing way to improve vector transduction efficiency would be the use of replicating viruses. Replicating oncolytic viruses can mediate direct killing of tumor cells, and may or may not carry additional therapeutic genes. Replicating viruses carrying therapeutic transgenes, so-called ''armed'' viruses, 5 may mediate tumor cell killing or induction of other physiological responses such as the stimulation of an antitumor immune response. Here, the idea is that as virus replicates and multiplies after establishment of the initial infection, the transgene will be amplified by virus spread through the solid tumors. However, for safety reasons, the replication of viruses should be tightly controlled and restricted to tumor cells. Thus, in recent years a number of conditionally replicating oncolytic viruses have been created including adenoviruses, herpes simplex viruses (HSV) and reoviruses. [6] [7] [8] Such antitumoral agents preferentially replicate in tumor cells and have been shown to mediate tumor regression both in preclinical animal models and in humans after intratumoral injection. [6] [7] [8] Furthermore, numerous experimental studies have demonstrated that this tumor-killing efficacy can be augmented significantly by incorporation of potentially therapeutic genes such as prodrug activators, for example, HSV thymidine kinase (HSV/tk) or bacterial cytosine deaminase (CD), as well as a variety of immunostimulatory molecules including granulocyte-macrophage colonystimulating factor (GM-CSF, Yoon et al, 6 Mullen et al 7 and Lin et al 8 )
. As an alternative to replicating conditionally oncolytic viruses derived from adenovirus, HSV or reovirus, replication-competent retrovirus (RCR)-based vectors derived from murine leukemia virus (MLV) have been proposed for use in cancer gene therapy. 5, 9, 10 RCRs efficiently integrate into host cell chromosomes, have a simple viral genome, are easy to modify and show low immunogenicity. Hence, their therapeutic use may have significant value in a variety of situations. Additionally, MLV-derived RCR can be endowed with antitumor lytic activity by incorporation into their genome of suicide genes such as the HSV/tk gene. 11, 12 It is well-documented that MLVs can replicate only in actively dividing cells. Therefore, appropriately targeted HSV/tk-expressing RCR vectors could be used to selectively kill infected tumor cells following prodrug administration, just like directly oncolytic viruses. On the other hand, the capability of RCRs to integrate into host DNA makes them ideal candidates for long-term genetic modification of tumor cells which may be a considerable advantage for a number of genebased strategies, for example, anti-angiogenesis treatment or protease inhibitor-based therapy. [13] [14] [15] [16] [17] However, and despite these properties, the applicability of RCR vectors in cancer gene therapy has been limited, primarily due to the instability of replicating retroviruses carrying additional transgenes. [18] [19] [20] Previous studies have shown that replicating MLV carrying transgene sequences between 100 to 1200 bp within the U3 region of the 3 0 long terminal repeat (LTR) usually lost their inserts within a few passages. However, unusually stable and efficiently growing MLV variants harboring an additional open reading frame (ORF) have been selected from a library of MLV variants displaying an epidermal growth factor (EGF)-derived domain at the N-terminus of the Env protein. EGF-displaying MLV variants encompassing furin cleavage sites within the linker peptide connecting the EGF domain and the surface Env glycoprotein have been selected from a suitable MLV library. 21 During production of the Env protein in infected cells, the EGF molecule is cleaved off during transport to the cell surface, whereby the cleaved EGF-domain is most likely directed into the secretory pathway. Given the fact that furin is a highly conserved, Golgi-anchored processing enzyme that is present in most eukaryotic cells, 22 any protein domain linked to the MLV Env protein via a furin-cleavable linker peptide would likely be produced in and secreted from infected cells. By adapting this system, reliable MLV-based RCR vectors suitable for delivering secretory therapeutic proteins inside a variety of tumors could possibly be generated.
In the present study, we sought to develop stable RCR vectors capable of mediating the secretion from infected cells of therapeutic molecules such as a particular singlechain antibody variable region fragment (scFv) or an immunostimulatory cytokine. To test secretion from infected cells, the L36-scFv specific for the basement membrane component laminin-1. 17, 23 and the 7A5-scFv specific for an as yet undefined T-cell surface antigen, 24 both selected from phage display libraries, were used. The cytokine GM-CSF was included as a model cytokine. We show here that replicating MLV vectors encompassing scFv or cytokine domains linked to the N-terminal domain of the retroviral Env protein by a furin-cleavable linker are infectious, retain their original cell tropism including cancer cell lines and are stable for at least 12 cell passages in cell culture. They mediate efficient secretion of biologically active proteins from the infected cancer cells.
Materials and methods

Cells and cell lines
The cell lines MDA-MB231 and MDA-MB468 (human breast cancer), A431 (human epidermoid carcinoma), HT1080 (human fibrosarcoma), 293T (human kidney epithelia), A301 (human T lymphoid cells) and murine lewis lung carcinoma (LLC) were obtained from the American Type Culture Collection. The HMEC-1 (human endothelia) cell line was a gift of Dr E Ades (Center for Disease Control, Atlanta, GA). All cells were cultivated in Dulbecco's modified Eagle's medium (DMEM, Gibco-BRL, UK), except HMEC-1 maintained in MCDB-131 endothelial cell-specific medium (Gibco) and A301 cells grown in RPMI 1640 medium, supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and antibiotics.
Construction of retroviral vector plasmids
An SfiI/NotI fragment comprising a fusion gene coding for L36 scFv (964 bp) or 7A5 scFv (982 bp) together inframe with an RGSHis tag (sequence: RGSHHHHHH ASS, Qiagen, Hilden) and the sequence encoding a furin recognition site (RLRRGSRk) selected from a retroviral protease substrate library, 21 was cloned into plasmid pE-A containing the amphotropic 4070A MLV env gene and the Moloney MLV gag and pol genes, resulting in pL36-furin-A and p7A5-furin-A plasmids, respectively (see Fig 1) . The SfiI/NotI fragments were generated by overlap extension PCR using the primer pairs-L36 sense: CATGCCATGACTCGCGGCCCAGCCGGCCATGG CCSAGGTSMARCTGCAGSAGTCWGG and L36-antisense: GCTGCTAGCGTGATGGTGATGGTGATGG CTTCCTCTACCTAGGACGGTCAGCTT, as well as 7A5 sense: ACTGCCCGAGCGGCCCAGCCGGCCATG GCCGAG and antisense: GCTGCTAGCGTGATGGT-G ATGGTGATGGCTTCCTCTCCGTTTTATTT CCAGC TT. After the first PCR, the coding sequences were amplified in a second PCR by using 1 ml of the PCR products as templates and respective sense primer and a common antisense primer: AGATTTCGCGGCCGCA CGGCTACCCCTCCGCAACCGGCTGCTAGCGTG ATGGTG-ATG. Afterwards, the resulting PCR products were subcloned into pGEM-T-easy (Boehringer Ingelheim Bioproducts Partnership, Heidelberg, Germany). After SfiI/NotI digestion, the fragments were ligated into the correspondingly digested pE-A plasmid. A similar strategy was used to clone the murine GM-CSF-encoding cDNA (Invivogen) in-frame with the furin cleavage motif into the plasmid pE-Mo resulting in pGMCSF-furin-Mo plasmid. All PCRs were performed with Taq-polymerase (Perkin Elmer, Vaterstetten) and the integrity of the constructs was verified by sequencing.
Production of virus vectors
In all, 5 Â 10 5 293T cells were transfected with 3 mg of the RCR-expressing plasmids using lipofectAMINE (Gibco-BRL, Eggenstein), according to the manufacturer's instructions. At 2 days after transfection, viral supernatants were harvested, filtered through 0.45-mm pore size syringe filters, and used to transduce HT1080 cells in the presence of 8 mg/ml of Polybrene (Sigma, St Louis, MO). Once cells were grown to confluency, they were maintained in serum-free DMEM medium for 4 to 5 days. Viral supernatant harvested from the cells was filtered and frozen (À801C) for use in all experiments, unless otherwise indicated.
Indirect immunofluorescence analysis
To determine bioactivity of the 7A5-scFv, 2 Â 10 6 /ml of A301 cells or irrelevant HMEC cells were incubated with 7A5-scFv viral supernatant for 1 hour at 41C. After washing, cells were subjected to 30 minutes of incubation at 41C with the anti-His-tag antibody (Qiagen) diluted 1:100 in washing buffer (2% FCS, 0.01% NaN3, in PBS). Antigen-antibody complexes formed on the cell surface were detected by additional 30 minute incubation (41C) with the ck antibody conjugated with R-phycoerythrin (BD, Heidelberg, Germany), followed by washing and fixation procedure with 1% paraformaldehyde/PBS, and analyzed on a FACScan (Becton Dickinson, San Jose, CA) using Lysis II software.
ELISA
To determine bioactivity of cellular L36-scFv in viral supernatants, 24-well plates (BD Falcon, Heidelberg, Germany) were precoated overnight with 10 mg/ml laminin-1 protein (BD Bioscience, Bedford, MA) at 41C, and after washing, were blocked for 2 hours at room temperature (RT) with 4% milkpowder (Roth, Karlsruhe)-containing PBS solution. L36-scFv-containing viral supernatant was then added to plates for binding. rL36-scFv harboring AAAHHHHHHGAA polyhistidine tag sequence (different from RGSHis tag) was produced from bacteria and used as a control. After 1 hour incubation at RT, unbound scFvs were washed off with PBST buffer (PBS containing 1% milkpowder and 0.05% Tween 20) and wells were then incubated for an additional 1 hour with 10 mg/ml of the capture antibodies (aHis-tag (Qiagen), or a myc-tag (9E10, Invitrogen, Carlsbad, CA, USA)) in washing buffer. For visualization of antigen-antibody complexes, a detection antibody -the rabbit anti-goat immune serum conjugated with horseradish peroxidase (HRP, 1:1000 dilution) (DAKO, Denmark) -and OPD substrate (Sigma) were used. Colorimetric response was read at 490 nm wavelength. The content of GM-CSF in viral supernatant was measured by using a commercially available ELISA kit (R&D Systems, Heidelberg, Germany).
Western blots
For analysis of scFv fragment expression, 20 ml of viral supernatants in serum-free medium was seperated on an 11% SDS-polyacrylamide gel and electotransferred onto a nitrocellulose membrane (Hybond ECL, Amersham Life Science, UK). After blocking with 10% of horseserum (GIBCO BRL) in PBST buffer, the membrane was incubated at RT with anti-RGSHis-tag antibody (Qiagen, 1:2000) in PBST containing 0.1% Tween 20. For visualization of antigen-antibody complexes, the HRPgoat anti-mouse immune serum conjugate was used (Sigma, at a dilution of 1:10,000). The blot was developed by using an enhanced chemiluminescence kit SuperSignal (Pierce), according to the manufacturer's protocol.
Immunohistochemistry for detection of virus infection
Virus infection was determined by the immunohistochemistry technique as described 25 with minor modification. Briefly, target cells were preseeded 1 day before into the 24-well culture plate at a density of approximately 1 Â 10 5 per well. On the next day, cells were incubated with viral supernatant for 4 to 5 hours at 371C in a final volume of 250 ml serum-free DMEM with 8 mg/ml Polybrene. After washing off virus-containing medium, cells were cultivated in 10% FCS DMEM medium for 2 to 5 days to allow spread of virus from infected cells to neighboring cells. Then, infected cells were fixed and permeabilized with ice-cold methanol (45 minutes), and were incubated with goat anti-RLV-p30 serum (1:200, Quality, Biotech) directed against retroviral capsid protein p30. Infected cells (in red color) were visualized by using the abovedescribed detection antibody (1:1000) and the substrate.
Results
Rationale for the design of scFv-and cytokine-producing RCR vectors
We hypothesized that in RCR vector-infected cells, scFvEnv or cytokine-Env fusion proteins synthesized in the endoplasmic reticulum would be transported to the Golgi apartment, where furin-mediated cleavage would occur to remove the scFv or cytokine domains, respectively, from the Env protein. With continuous release of the infectious retrovirus from the initially infected cells, more cells would be infected and as a consequence, increasing amounts of the scFv or cytokine would accumulate in culture supernatants (Fig 1a) .
To generate RCR vectors able to deliver efficiently genes encoding secreted products, we developed a fusion gene-derived cDNA encoding the scFv fragment, an RGSHis-tag (RGSHHHHHHASS), and, as a linker connecting both, a peptide representing the furin cleavage site (RLRRGSRk) previously selected from MLV display libraries. 21 This cDNA was inserted directly 3 0 of the þ 1 amino-terminal codon of the amphotropic (4070A) retroviral env gene, resulting in replicating MLV vectors designated L36-furin-A and 7A5-furin-A, respectively (Fig 1b) . The RGSHis sequence was necessary to detect easily secreted scFvs in infected cell culture supernatants. The GMCSF-furin-Mo virus vector was constructed in a similar way using the ecotropic Moloney MLV, but was devoid of the RGSHis sequence.
Efficiency of fusion protein processing and secretion of gene products from RCR vector-infected cells
RCR vector stocks to be tested for mediating scFv secretion were prepared by transfection of 293T cells with the L36-furin-A or the 7A5-furin-A plasmid, respectively (3 mg/5 Â 10 5 cells). After 48 hours, culture supernatants were harvested and used for infection of human HT1080 fibrosarcoma cells. Upon reaching confluency, infected cultures were maintained in serum-free medium for 4 to 5 days. The GMCSF-furin-Mo virus was produced by transfection of murine LLC cells with the GMCSFfurin-Mo plasmid and cultivation of the cells until they reached confluency. All culture supernatants were used as RCR vector stocks for further analyses.
Proteolytic processing of the scFv-Env fusion proteins was first assessed by Western blot analysis, using RCR vector-containing supernatants and a primary antibody directed against the RGSHis-tag sequence (Fig 2a) . A strong band at approximately 29 kDa corresponding to the L36-scFv fragment was indeed detected in the supernatant of L36-furin-A-infected cells (lane 1). A weak band at the size of approximately 100 kDa (lane 1, upper band) corresponding to the uncleaved scFv-Env fusion protein was also detected, suggesting the existence of intact fusion protein in a minor proportion of L36-furin-A viruses in cell supernatants. In accordance with this, we found that, after filtration of the infected cell culture supernatants, uncleaved scFv-Env protein containing viruses could only be detected in the fraction containing large proteins of 450 kDa size (Fig 2a, compare lanes 2, 4  and 5) . In culture supernatants of 7A5-furin-A-infected cells, a strong band of about 30 kDa corresponding to the 7A5-scFv was exclusively detected (Fig 2a, lane 3) , with no detectable 7A5-Envfusion protein present. Importantly, in both cases, no degradation products that could have resulted either from intra-or extra-cellular processing or from the deletion of the scFv-encoding cDNAs due to RCR vector genome instability were observed. In Protein delivery by replicating retrovirus C Finger et al conclusion, secreted scFv fragments were found in the culture supernatants of L36-furin-A-and 7A5-furin-Ainfected cells, indicating highly efficient cleavage and secretion of foreign scFv domains expressed as scFv-Env fusion proteins in infected cells.
To determine the quantity of scFv molecules released from infected cells, we titrated a His-tagged protein ladder and compared the signal strength of respective bands with that of the L36-scFv recovered from varying amounts of L36-furin-A-infected cell supernatant in a semiquantitative immunoblot analysis (Fig 2b) . By comparing signal intensities, we estimated the level of L36-scFv released from L36-furin-A-infected cells to be in a range between 3 and 4 mg per ml. The levels of GM-CSF produced by GMCSF-furin-Mo-infected cells were assessed by direct ELISA, showing up to 650 pg/ml of the cytokine in the culture supernatant already 2 days after transfection (Fig 2c) . In contrast, no GM-CSF was detected in culture supernatants of untransfected cells or cells transfected with mock plasmid (Fig 2c) . Taken together, these results showed that cells infected with the three RCR vectors generated were able to process efficiently the encoded Env fusion proteins and release reasonable amounts of protein molecules into the cell culture media.
Functionality of scFvs produced by RCR vector-infected cells
To examine whether the scFvs released into the supernatants of RCR vector-infected cells were biologically active, we studied the reactivity of protein recovered from unconcentrated supernatants toward native antigens. As it has previously been shown that the antigenic epitopes of laminin-1 protein are not altered upon coating to plastic wells, 23 we tested the binding of L36-scFv in the supernatant of L36-furin-A-infected cells to laminin-1-coated plates (at 10 mg/ml) by ELISA. Figure 3a shows that addition of L36-scFv-containing supernatant resulted in strong staining comparable to that observed with bacterially produced rL36-scFv detected with antibody 9E1 (see wells 1 and 3, Fig 3a) . In contrast, anti-RGDHis antibody showed weak binding affinity to the same rL36-scFv probe, revealed by a weaker color reaction (well 2). This was ascribed to the different polyhistidine tag sequences in rL36-scFv and in L36-scFv produced by L36-furin-A-infected cells. In contrast, neither the 7A5-scFv nor the noninfected cell supernatant sample reacted with laminin-1 (wells 4 and 5). In indirect fluorescene analysis, treatment of cells with 7A5-scFv supernatant led Protein delivery by replicating retrovirus C Finger et al to significantly enhanced fluorescence with the T-cell line A301, while it did not react with antigen negative HMEC-1 cells (Fig 3b) . These results strongly indicated that both types of scFv molecules, once secreted from infected cells, were biologically active and specifically reacted with immobilized and in vivo presented cell surface antigens.
Infectivity of 7A5-scFv-and L36-scFv-encoding RCR vectors in different human cell types
To analyze infection activity and fusion protein processing of the RCR vectors in different human cells, four human tumor cell lines (HT1080, MDA-MB231, MDA-MB468, A431), one epithelia cell line (293T) and one endothelia cell line (HMEC-1) were selected. The L36-scFv-and 7A5-scFv-encoding RCR vectors were tested because, due to the amphotropic nature of their Env, they were suitable for infecting human tumor cells. To measure infectivity, we incubated cells with culture supernatants containing one of the two selected RCR vectors for 2 days, followed by immune staining against the retroviral capsid protein p30 known to be expressed after MLV infection. As shown in Figure 4a , all six cell lines were permissive for L36-furin-A vector infection and exhibited various degrees of p30 staining. In 7A5-furin-A-treated cultures, a relatively high number of p30-positive cells were observed only in the HT1080 and the HMEC-1 cultures (Fig 4a) . However, prolongation of the infection time to 5 days led to 100% infection of all six cell types by 7A5-furin-A vector (data not shown). In contrast, noninfected cell cultures (as controls) were consistently negative for p30 staining. Taken together, these results suggested different degrees of permissiveness to both RCR vectors of the different cell types tested.
To ascertain whether all of the different cell types were able to process and secrete the encoded therapeutic gene products upon infection, supernatants containing scFvs were collected 2 days after infection and analyzed (Fig 4b) . With a primary antibody directed against the RGSHis tag, the specific immunostaining for the L36-scFv fragment was evident in all six culture supernatants infected with L36-furin-A (lane 1, Fig 4b) . In contrast, the 7A5 scFv-associated signal was detected in the viral supernatants of HMEC-1, HT1080 and, albeit marginally, in MDA-MB-468 cells, but not in the viral supernatants of 293T, A431 and MDA-MB-231 cells. Overall, the level Protein delivery by replicating retrovirus C Finger et al of the respective scFv detected correlated well with the varying degrees of infection as described above. There was one exception, namely the HMEC-1-infected culture where only trace amounts of L36-scFv were detected. Since HMEC-1 cells have been demonstrated to express laminin [26] [27] [28] and given the fact that the cellular L36-scFv had been found to react with laminin-1 (Fig 3a) , it was assumed that substantial amounts of the L36-scFv produced were tightly associated with HMEC-1 cells, thereby leaving only small and therefore undetectable levels of unbound L36-scFv in the supernatant. In summary, these results suggested that a variety of tumor cells were permissive for L36-furin-A and 7A5-furin-A RCR vector infection, and could secrete functional scFvs.
Stability of L36-furin-A and 7A5-furin-A RCR vectors during passages
Since previous work had indicated that RCR vectors may display a high degree of genetic instability and eliminate the inserted sequences upon spread through susceptible cells, [18] [19] [20] 29, 30 we determined whether the RCR vectors generated were sufficiently stable to allow long-term delivery of the encoded therapeutic gene products. To this Figure 4 Infectibility and the capability of a variety of human cell types to process scFv-SU fusion proteins. (a) In all, 2-day culture supernatant of 293T cells transfected with or without pL36-furin-A or p7A5-furin-A plasmid was used to infect six different human cell lines as indicated. At 2 days after infection, infected cells were subjected to immunohisto-chemistry using goat anti-RLV-p30 sera (primary antibody) and rabbit anti-goat immune sera/horseradish peroxidase conjugate (second antibody). (b) In parallel, L36-scFv and 7A5-scFv fragments in corresponding viral supernatant (unconcentrated) were analyzed by immunoblot using a primary anti-RGSHis tag antibody. Only o30 kDa bands are shown.
Protein delivery by replicating retrovirus C Finger et al end, we prepared viral RNA from L36-furin-A and 7A5-furin-A virions harvested from multiple serially infected HT1080 cultures. A total of 12 consecutive infections were conducted in which a 100-fold dilution of supernatant from each infection cycle was used to infect the subsequent cell population (Fig 5a) . RT-PCR was performed to amplify specific regions of the viral mRNA using suitable primer pairs. All 12 L36-furin-A samples displayed a unique 964 bp band specific for the L36-scFvcoding region, with no deletion of the inserted sequence detected (Fig 5b) . The same was true for all 12 7A5-furin-A samples uniformly showing the expected 982 bp band (Fig 5b) . Western blot analysis of the viral supernatants collected from the last infection cycle revealed that L36-scFv and 7A5-scFv fragments were produced in the culture supernatants (data not shown). Thus, even after 12 serial cycles of propagation, that is, a total theoretical amplification by a factor of 10 14 , both RCR vectors tested were still genetically stable and kept the ability to mediate production and secretion of functional proteins.
Discussion
We report here the generation and characterization of RCR vectors able to efficiently mediate intracellular production and secretion of functional antibodies (L36-scFv and 7A5-scFv) or the cytokine GM-CSF. The RCR vector genomes were constructed by fusing specific gene sequences to the þ 1 codon of the MLV env gene via a furin protease cleavage site. The resulting vectors were capable of efficiently transducing susceptible cancer cells over multiple passages resulting in intracellular production and secretion of the particular scFv or GM-CSF, respectively. The identity of the secreted gene products was demonstrated by showing specific binding of the scFvs to the respective native antigens they recognize.
RCR vectors with notable genomic stablity have been developed recently from amphotropic MLV. [31] [32] [33] According to these studies, the stability of these RCR vectors is determined by both the proper insertion site and the size of the inserted sequences. Logg et al 31 initially demonstrated that positioning a 1.3-kb cDNA precisely at the boundary between env and the 3 0 UTR regions confers upon an RCR vector the ability to tolerate exogenous sequence. In contrast, retroviral vectors with insertions in the U3 region of the 3 0 LTR [18] [19] [20] 29, 30 are less stable. It has further been shown that an RCR vector encompassing a a large insertion (1.55 kb) at the same insertion site displayed greatly attenuated replication kinetics and lost inserts even in a single infection cycle, as compared with vectors containing inserts of 1.15 to 1.3 kb or less. 32 Hence, it seems plausible that the replicative fitness of engineered viruses may contribute to a large degree to the greater genomic stability. The results presented here extend these observations by demonstrating that RCR vectors created by strategical selection of a furin site from randomized libraries can be stable over Z12 cycles of infection. Since furin is a cellular protease involved in the processing of various secretory proteins in most eukarytic Protein delivery by replicating retrovirus C Finger et al cells, 22, [34] [35] [36] it is conceivable that a variety of peptides including the ones tested here fused to the Env protein via an RLRRGSR cleavage site (L36-scFv, 7A5-scFv, GM-CSF) can be efficiently cleaved off from chimeric Env protein without inhibiting viral infection, as assessed here in a variety of cell types (Figs 2-4) . Hence, RCR vector replication in susceptible cells is accompanied by a tremendous amplification of gene distribution in target cells and delivery of secretory bioactive proteins. To our knowledge, this is the first report on the potential and the utility of RCR vectors in continuously achieving a large quantity of secreted gene products. Furthermore, the retained vector infectivity also makes such RCR vectors highly suitable for application in a variety of tumor types.
The infectivity of retroviruses displaying foreign polypeptides as N-terminal extension of their SU protein depends on both the structure and the biological function of the displayed polypeptide. 37 Dimeric or trimeric molecules, for example, are more efficient in blocking infectivity than monomers (scFv molecules are usually monomers but can form dimers). On the other hand, monomers with high affinity for certain cell surface receptors can also strongly impair infectivity, while small peptides usually do not. The few additional amino-acid residues remaining at the N-terminus of the SU protein after furin cleavage therefore should not influence infection. It is not known from which fraction of SU molecules a ligand that blocks infectivity must be cleaved off to fully restore infection. In case of furin cleavable ligands, the cleavage efficiency varies depending on the type of polypeptide displayed. While the L36 was only partially removed by furin (about 50%), the chemokine CXCL-10 was completely removed when a corresponding construct was established and investigated (Sun and Buchholz, unpublished).
Examination of RCR vector infectivity in different human cells revealed an advantage of L36-furin-A RCR vector relative to the 7A5-furin-A vector. This difference may be due in part to the binding of a minority of uncleaved L36-scFv-displaying viruses to laminin-1. In fact, we have observed that binding of the ecotropic Mo-MLV to laminin-1 enhanced virus infectivity (Urban and Buchholz, unpublished). A similar observation was also made by Murray et al 38 who showed that retrovirus binding to RetroNectin -a component of extracellular matrix -enhances virus infectivity. However, complete infection by 7A5-furin-A vector of all six human cell cultures could be achieved 5 days after infection, suggesting that all cell types tested were permissive for this vector infection (data not shown). The observation that HT1080 and HMEC-1 cells were more apparently infected by 7A5-furin-A vector by 2 days of infection (Fig 4) may be partially due to the enhanced susceptibility of these cells, or by increased expression of furin protease in these cells, or both. Whatever the reasons may, however, it is clear that this structure does not interfere with the 7A5-furin-A RCR vector stability and replicative capabilities when propagated on its susceptible cells (Fig 5) .
We have observed that the RCR vectors transduced normal fibroblasts and endothelial cells apparently as efficiently as the tumor cells themselves (Fig 4, and data not shown). Since these cells are abundantly present in the close vicinity of tumor cells and known as the major cellular components contributing to aggressive tumor growth and invasion, achieving gene delivery to these nontumorigenic cells within or surrounding tumor compartments may be advantageous in certain situations, for instance, for antiangiogenesis therapy and protease inhibitor-based strategies. Numerous experimental and clinical studies have indicated that the therapeutic efficacies of such treatment modalities essentially require continuous delivery of a large quantity of secretory therapeutic molecules. [13] [14] [15] [16] [17] Hence, gene delivery to endothelial cells should be able to allow boosting of the antiangiogenesis effect by their direct and durable transmission of the introduced therapeutic genes.
Certainly, uncontrolled spread of RCR vectors has the potential to result in insertional oncogenesis, as witnessed by the occasional development of vector-related malignancies both in macaques and in human beings receiving gene replacement therapy. 39, 40 However, this oncogenic concern is mitigated by a number of considerations when contemplating the application of RCR vectors in anticancer gene therapy. First, MLV-derived RCR vectors possess the unique property of infecting solely mitotically active cells, and hence have natural selectivity for dividing tumorous or neovascular endothelial cells. In this context, it is worthwhile noting that intratumoral injection of untargeted MLV-derived RCR vectors in athymic nu/nu mice have led to highly efficient and progressive in situ vector transduction in two independent studies; however, in each study extratumoral spread was not detected. 31, 33 Second, the tumor microenvironment itself is known to be inherently immunosuppressive, and thus it is possible that RCR vector spread would be confined to the tumor tissue, while extratumoral spread would be restricted by the immune system. Furthermore, the tumor selectivity of RCR vector spread can be further improved by targeting vectors at different levels such as at cell entry 25, 37, 41 or incorporation of cell-type-and tissue-specific transcriptional control elements. [42] [43] [44] The availability of appropriately targeted RCR vectors would facilitate the design of therapeutically effective protocols for gene therapy of cancer.
